作者对新型抗菌药DL8280(ofloxacin)治疗肺结核的疗效进行了探讨。他们给19名慢性空洞肺结核患者连续服用DL8280 6～8个月,每日300毫克,结果几乎所有患者的痰结核菌均有所减少,其中5例结核菌阴转。虽然结核菌未见阴转的病人出现了耐药性,但并未出现副作用。目前认为,该药作为抗结核药物也是可用的。方法治疗对象为19例对各种抗结核剂皆产生耐药性、治疗无效、有空洞的肺结核排 The author of the new antibacterial DL8280 (ofloxacin) treatment of pulmonary tuberculosis were discussed. They administered DL8280 to 6 patients with chronic vCB for 6-8 months, 300 milligrams daily, resulting in a decrease in sputum TB in almost all patients, of whom 5 were overtaxed. Although there was no drug resistance in patients with TB that did not overturn, no side effects occurred. It is currently believed that the drug is also available as an anti-TB drug. Methods The treatment of 19 cases of various anti-TB agents are resistant to treatment, treatment ineffective, empty tuberculosis row